Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 3494 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

EDUCATIONAL FORUM

Use of Bayesian statistics in drug development: Advantages and challenges

Gupta Sandeep K

Year : 2012| Volume: 2| Issue : 1 | Page no: 3-6

   This article has been cited by
 
1 How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease
Anna G. M. Temp, Michael W. Lutz, Dominic Trepel, Yi Tang, Eric-Jan Wagenmakers, Ara S. Khachaturian, Stefan Teipel
Alzheimer's & Dementia. 2021; 17(6): 917
[Pubmed]  [Google Scholar] [DOI]
2 Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges
Moreno Ursino,Nigel Stallard
International Journal of Environmental Research and Public Health. 2021; 18(3): 1022
[Pubmed]  [Google Scholar] [DOI]
3 Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine
Ryuji Hamamoto,Kruthi Suvarna,Masayoshi Yamada,Kazuma Kobayashi,Norio Shinkai,Mototaka Miyake,Masamichi Takahashi,Shunichi Jinnai,Ryo Shimoyama,Akira Sakai,Ken Takasawa,Amina Bolatkan,Kanto Shozu,Ai Dozen,Hidenori Machino,Satoshi Takahashi,Ken Asada,Masaaki Komatsu,Jun Sese,Syuzo Kaneko
Cancers. 2020; 12(12): 3532
[Pubmed]  [Google Scholar] [DOI]
4 Developments in evidence creation for treatments of inborn errors of metabolism
Sylvia Stockler-Ipsiroglu,Beth K. Potter,Nataliya Yuskiv,Kylie Tingley,Marc Patterson,Clara Karnebeek
Journal of Inherited Metabolic Disease. 2020;
[Pubmed]  [Google Scholar] [DOI]
5 Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system
M. J. Mulcahey,Linda A. T. Jones,Frank Rockhold,R?ediger Rupp,John L. K. Kramer,Steven Kirshblum,Andrew Blight,Daniel Lammertse,James D. Guest,John D. Steeves
Spinal Cord. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Cell Therapies for Spinal Cord Injury: Trends and Challenges of Current Clinical Trials
Richard D Bartlett,Sarah Burley,Mina Ip,James B Phillips,David Choi
Neurosurgery. 2020;
[Pubmed]  [Google Scholar] [DOI]
7 Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer
Jianqing Lin,Robert B. Den,Jacob Greenspan,Timothy N. Showalter,Jean H. Hoffman-Censits,Costas D. Lallas,Edouard J. Trabulsi,Leonard G. Gomella,Mark D. Hurwitz,Benjamin Leiby,Adam P. Dicker,W. Kevin Kelly
International Journal of Radiation Oncology*Biology*Physics. 2020;
[Pubmed]  [Google Scholar] [DOI]
8 Potential harm caused by physiciansæ a-priori beliefs in the clinical effectiveness of hydroxychloroquine and its impact on clinical and economic outcome – A simulation approach
Ebm Claudia,Carfagna Fabio,Edwards Sarah,Alberto Mantovani,Cecconi Maurizio
Journal of Critical Care. 2020;
[Pubmed]  [Google Scholar] [DOI]
9 Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations
Anastacia M. Garcia,Jonathan-Thomas Beatty,Stephanie J. Nakano
American Journal of Physiology-Heart and Circulatory Physiology. 2020; 318(4): H947
[Pubmed]  [Google Scholar] [DOI]
10 Major Outcomes With Personalized Dialysate TEMPerature (MyTEMP): Rationale and Design of a Pragmatic, Registry-Based, Cluster Randomized Controlled Trial
Ahmed A. Al-Jaishi, Christopher W. McIntyre, Jessica M. Sontrop, Stephanie N. Dixon, Sierra Anderson, Amit Bagga, Derek Benjamin, David Berry, Peter G. Blake, Laura Chambers, Patricia C. K. Chan, Nicole Delbrouck, P. J. Devereaux, Luis F. Ferreira-Divino, Richard Goluch, Laura Gregor, Jeremy M. Grimshaw, Garth Hanson, Eduard Iliescu, Arsh K. Jain, Charmaine E. Lok, Reem A. Mustafa, Bharat Nathoo, Gihad E. Nesrallah, Matthew J. Oliver, Sanjay Pandeya, Malvinder S. Parmar, David Perkins, Justin Presseau, Eli Rabin, Joanna Sasal, Tanya Shulman, Manish M. Sood, Andrew Steele, Paul Tam, Daniel Tascona, Davinder Wadehra, Ron Wald, Michael Walsh, Paul Watson, Walter Wodchis, Phillip Zager, Merrick Zwarenstein, Amit X. Garg
Canadian Journal of Kidney Health and Disease. 2020; 7: 2054358119
[Pubmed]  [Google Scholar] [DOI]
11 Artificial Intelligence in Clinical Health Care Applications: Viewpoint
Michael van Hartskamp,Sergio Consoli,Wim Verhaegh,Milan Petkovic,Anja van de Stolpe
Interactive Journal of Medical Research. 2019; 8(2): e12100
[Pubmed]  [Google Scholar] [DOI]
12 Alirocumab, Decreased Mortality, Nominal Significance, P Values, Bayesian Statistics, and the Duplicity of Multiplicity
Harold Edward Bays
Circulation. 2019; 140(2): 113
[Pubmed]  [Google Scholar] [DOI]
13 Pediatric Heart Failure: An Evolving Public Health Concern
Stephanie J. Nakano,Shelley D. Miyamoto,Jack F. Price,Joseph W. Rossano,Antonio G. Cabrera
The Journal of Pediatrics. 2019;
[Pubmed]  [Google Scholar] [DOI]
14 Gingyogedokusan versus oseltamivir for the treatment of influenza: Bayesian inference using the Markov chain Monte Carlo method with prior pilot study data
Kentaro Iwata,Takashi Nishimoto,Kumi Higasa,Seiichiro Usuki,Chisato Miyakoshi
Traditional & Kampo Medicine. 2019;
[Pubmed]  [Google Scholar] [DOI]
15 Promising Results from Alzheimer’s Disease Passive Immunotherapy Support the Development of a Preventive Vaccine
D. J. Marciani
Research. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
16 Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach
Annette Kopp-Schneider,Manuel Wiesenfarth,Ruth Witt,Dominic Edelmann,Olaf Witt,Ulrich Abel
Biometrical Journal. 2018;
[Pubmed]  [Google Scholar] [DOI]
17 Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle
Imke H. Bartelink,Ella F. Jones,Sheerin K. Shahidi-Latham,Pei Rong Evelyn Lee,Yanan Zheng,Paolo Vicini,Laura van ‘t Veer,Denise Wolf,Andrei Iagaru,Deanna L. Kroetz,Brendan Prideaux,Cornelius Cilliers,Greg M. Thurber,Zena Wimana,Geraldine Gebhart
Clinical Pharmacology & Therapeutics. 2018;
[Pubmed]  [Google Scholar] [DOI]
18 Evolving paradigms for new agent development in pediatric oncology
Andrea Flynn,Elizabeth Fox
Current Opinion in Pediatrics. 2018; 30(1): 10
[Pubmed]  [Google Scholar] [DOI]
19 Bayesian adaptive trials for rare cardiovascular conditions
Azadeh Shohoudi,David A Stephens,Paul Khairy
Future Cardiology. 2018; 14(2): 143
[Pubmed]  [Google Scholar] [DOI]
20 Rationale of a Novel Study Design for the BIOFLOW V Study, a Prospective, Randomized Multicenter Study to Assess the Safety and Efficacy of the Orsiro Sirolimus-Eluting Coronary Stent System Utilizing a Bayesian Approach
Gheorghe Doros,Joseph M. Massaro,David E. Kandzari,Ron Waksman,Jacques J. Koolen,Donald E. Cutlip,Laura Mauri
American Heart Journal. 2017;
[Pubmed]  [Google Scholar] [DOI]
21 Integration of PKPD relationships into benefit-risk analysis
Francesco Bellanti,Rob C. van Wijk,Meindert Danhof,Oscar Della Pasqua
British Journal of Clinical Pharmacology. 2015; 80(5): 979
[Pubmed]  [Google Scholar] [DOI]
22 Trends in epidemiology in the 21st century: time to adopt Bayesian methods
Edson Zangiacomi Martinez,Jorge Alberto Achcar
Cadernos de Saúde Pública. 2014; 30(4): 703
[Pubmed]  [Google Scholar] [DOI]

 

Read this article